All Articles
On September 21, 2022, the FDA accelerated the approval of selpercatinib (Retevmo; Eli Lilly), a selective RET kinase inhibitor, for the treatment of all locally advanced or metastatic solid tumors with a RET gene fusion in patients whose disease progressed during or after systemic treatment or who have no alternative treatment options. Read More ›
On September 20, 2022, the FDA approved sodium thiosulfate (Pedmark; Fennec Pharmaceuticals), an
inorganic sodium salt, for risk reduction of hearing loss (ototoxicity) associated with cisplatin treatment in children aged ≥1 month to 18 years with nonmetastatic solid tumors. Read More ›
On September 28, 2022, the FDA approved bevacizumab-adcd (Vegzelma; Celltrion), a VEGF inhibitor and a biosimilar to bevacizumab (Avastin), for the treatment of metastatic colorectal cancer; recurrent or metastatic non-squamous non–small-cell lung cancer (NSCLC); recurrent glioblastoma; metastatic renal-cell carcinoma; persistent, recurrent, or metastatic cervical cancer; and epithelial ovarian, fallopian tube, or primary peritoneal cancer. Read More ›
On September 30, 2022, the FDA accelerated the approval of futibatinib (Lytgobi; Taiho Oncology), a tyrosine kinase inhibitor, for the treatment of adults with previously treated unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma (CCA) and FGFR2 gene fusion or other rearrangements. Read More ›
A single-institution experience in treating patients with metastatic iCCA with local liver-directed radiation therapy (RT) was presented by Rituraj Upadhyay, MD, at the 2022 American Society of Clinical Oncology Annual Meeting. Read More ›
By William King
In a special symposium held during the European Society for Medical Oncology Congress 2022, experts discussed lessons learned in the diagnosis and treatment of patients with primary brain tumors and what is on the horizon. Read More ›
Navigating the health insurance landscape in the United States is confusing—and particularly so in light of the ever-changing expansions under the Affordable Care Act (ACA)—but understanding the many existing disparities in cancer-related care and coverage can help providers to offer the best care possible to their patients and to find solutions for those who might be getting left behind. Read More ›
On September 21, 2022, the Association for Accessible Medicines (AAM), the leading
trade association for generic and biosimilar manufacturers, released its 2022 U.S. Generic & Biosimilar Medicines Savings Report highlighting the value of generic and biosimilar medicines. Read More ›
By William King
Providers participating in the Centers for Medicare & Medicaid Services’ (CMS’) value-based payment (VBP) models may realize a reduction in financial risk via biosimilar substitution. Read More ›
By William King
The increased use of biosimilars within the US Oncology Network generated more than $6 million of savings in the Centers for Medicare & Medicaid Services’ Oncology Care Model (OCM) during the first half of 2020. Read More ›